



FOR IMMEDIATE RELEASE

October 30, 2024

Listed Company Name: Eisai Co., Ltd.
Representative: Haruo Naito
Representative Corporate
Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo
Stock Exchange
Inquiries: Sayoko Sasaki
Vice President,
Corporate Communications
Phone +81-3-3817-5120

REVENUE OF LEQEMBI® (PRELIMINARY BASIS)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue of the anti-amyloid-beta protofibril antibody "LEQEMBI®" (generic name: lecanemab) in the second quarter of fiscal year 2024 (July 1, 2024 – September 30, 2024) was JPY 10.0 billion (pre-audit basis), which was approximately 1.6 times higher than the revenue in the previous quarter of fiscal year 2024 (April 1, 2024 – June 30, 2024).

This information is being disclosed in conjunction with today's announcement of the financial results for the third quarter of 2024 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai's financial results for the second quarter of fiscal year 2024, including details of LEQEMBI's revenue, will be disclosed in Eisai's financial disclosure scheduled for November 8, 2024.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
